Data evento: 10 giugno 2021, in modalità e-learning
The treatment of chronic HCV infection has been revolutionized by the development of the directly acting antivirals (DAAs) that led to efficacy expectations approaching 100% with just 8 or 12 weeks of treatment.
The currently available regimens for the therapy of treatment-naïve patients consist of
twodrug regimens available only in co-formulation, while a three-drug co-formulation has been developed for more complex virologic patterns.
Sito ufficiale
https://www.nadirexecm.it/eventi/hcv_controversies
Hai trovato utile questo articolo?
